Characteristics of recipients and donors
| . | Recipients, n = 44 . | Donors, n = 44 . |
|---|---|---|
| Sex | ||
| Female, n (%) | 20 (45.5) | 24 (54.5) |
| Male, n (%) | 24 (54.5) | 20 (45.5) |
| Median age at HSCT, y (range) | 26.8 (5-50) | 25.8 (2-46) |
| Median age at the examination, y (range) | 44.3 (24-63) | 43.4 (22-61) |
| Median follow-up after HSCT, y (range) | 17.5 (11-26) | |
| Diagnosis, n (%) | ||
| Severe aplastic anemia | 4 (10) | |
| Hematologic malignancies | 40 (90) | |
| Acute myeloblastic leukemia | 16 (36) | |
| Chronic myeloid leukemia | 11 (25) | |
| Acute lymphoblastic leukemia | 7 (16) | |
| Non-Hodgkin lymphoma | 3 (7) | |
| Chronic lymphocytic leukemia | 1 (2) | |
| Myelodysplastic syndrome | 2 (4) | |
| TBI, n (%) | ||
| Yes | 39 (89) | |
| No | 5 (11) | |
| TBI fractionated/nonfractionated, n (%) | 28/11 (70/30) | |
| Source of stem cells: bone marrow, % | 100 | |
| Median nucleated cell dose infused, × 108/kg (range) | 4.2 (0.3-16.6) | |
| Donor type: human leukocyte antigen–identical sibling, % | 100 | |
| Acute GVHD, n (%) | ||
| None or grade I | 18 (41) | |
| Grade II-IV | 26 (59) | |
| Chronic GVHD, n (%) | ||
| None | 22 (50) | |
| Yes | 22 (50) | |
| Karnofsky score, n (%) | ||
| 100% | 38 (86.4) | 43 (97.7) |
| ≤ 90% | 6 (13.6) | 1 (2.3) |
| . | Recipients, n = 44 . | Donors, n = 44 . |
|---|---|---|
| Sex | ||
| Female, n (%) | 20 (45.5) | 24 (54.5) |
| Male, n (%) | 24 (54.5) | 20 (45.5) |
| Median age at HSCT, y (range) | 26.8 (5-50) | 25.8 (2-46) |
| Median age at the examination, y (range) | 44.3 (24-63) | 43.4 (22-61) |
| Median follow-up after HSCT, y (range) | 17.5 (11-26) | |
| Diagnosis, n (%) | ||
| Severe aplastic anemia | 4 (10) | |
| Hematologic malignancies | 40 (90) | |
| Acute myeloblastic leukemia | 16 (36) | |
| Chronic myeloid leukemia | 11 (25) | |
| Acute lymphoblastic leukemia | 7 (16) | |
| Non-Hodgkin lymphoma | 3 (7) | |
| Chronic lymphocytic leukemia | 1 (2) | |
| Myelodysplastic syndrome | 2 (4) | |
| TBI, n (%) | ||
| Yes | 39 (89) | |
| No | 5 (11) | |
| TBI fractionated/nonfractionated, n (%) | 28/11 (70/30) | |
| Source of stem cells: bone marrow, % | 100 | |
| Median nucleated cell dose infused, × 108/kg (range) | 4.2 (0.3-16.6) | |
| Donor type: human leukocyte antigen–identical sibling, % | 100 | |
| Acute GVHD, n (%) | ||
| None or grade I | 18 (41) | |
| Grade II-IV | 26 (59) | |
| Chronic GVHD, n (%) | ||
| None | 22 (50) | |
| Yes | 22 (50) | |
| Karnofsky score, n (%) | ||
| 100% | 38 (86.4) | 43 (97.7) |
| ≤ 90% | 6 (13.6) | 1 (2.3) |